ÂÜÀòÂÒÂ×

Jean-Michel joined the Board of Malin as Independent Non-Executive Director in July 2018.

Jean-Michel previously spent 10 years at GE Healthcare as the Chief Marketing Officer and VP, Global Marketing. More recently, he served as VP, North American Oncology with Eli Lilly, as well as Managing Director Northern Europe. He serves on the boards of Exact Tx, a medtech company listed in Norway; Diurnal Group plc, a specialty pharmaceutical company developing hormone therapeutics; SOPHiA GENETICS SA, a health care technology company based in Switzerland and EraCal Therapeutics Ltd, a biotech company based in Switzerland. Jean-Michel served on the board of Immunocore Limited in the UK until its IPO and on the board of Kymab Group Limited until its sale to Sanofi in 2021.

Jean-Michel holds an MBA from the Rotterdam School of Management (Erasmus University). He received his PhD with honours in Nuclear Chemistry and Neurobiology from the University of Paris and conducted post-doctoral research in Neuropharmacology at the National Institutes of Health in the US. Additionally, he holds a Pharm D with honours in Pharmacology from the University of Paris.